Skip to main content
. 2023 Oct 27;26(11):108299. doi: 10.1016/j.isci.2023.108299

Figure 4.

Figure 4

Impact of mutations in the Omicron BA.2.12.1 and BA.4/5 Spike on neutralization by sera and therapeutic Abs

(A) Neutralization of VSVpp carrying the indicated wild type and mutant S proteins by sera obtained from two AZN/BNT (left panel) and two BNT/BNT (right panel) vaccinated individuals compared to the untreated control (set to one). Infection was measured in Caco2 cells. Symbols represent the mean of technical duplicates. In the upper panel the Hu-based S variants are indicated while in the lower panel the BA.2-based variants.

(B) Changes in TCID50 values obtained for neutralization of the indicated mutant Hu-based (left panel) or BA.2-based (right panel) S proteins by sera from four vaccinated individuals relative to those obtained for the Hu-1 S. Symbols indicate individual donors and solid red bars indicate average values (±SEM) for the four sera.

(C) Close-up view of neutralizing antibodies binding the SARS-CoV-2 Spike (PDB: 7MMO; 6XDG; 7KMG), as indicated) and automated quantification of infection events of Caco2 cells transduced with VSVΔG-GFP pseudotyped with the indicated S variants. VSVpp were pre-treated (30 min, RT) with the indicated amounts of bebtelovimab, ikmdevimab, casivirimab, or bamlanivimab. Symbols represent the mean of three independent experiments (±SEM). (see also Figure S4).